Press release
Digital Therapeutics Market to Witness Transformative Growth Through 2032 - Market Insights, Competitive Landscape, and Forecast | DelveInsight
Digital Therapeutics Market
Innovations in AI-powered behavioral therapy, mobile health apps, remote monitoring platforms, and personalized digital interventions are reshaping patient care by enhancing engagement, improving adherence, and enabling scalable, cost-effective treatment models. Additionally, favorable regulatory frameworks, expanding reimbursement pathways, and growing clinical validation are fueling market momentum globally.
DelveInsight's Digital Therapeutics Market Insights report offers a comprehensive analysis of this evolving landscape, covering key trends, market drivers and barriers, regulatory developments, clinical innovations, and payer dynamics. The report also profiles leading and emerging players, providing insights into competitive strategies, partnerships, and pipeline progress to support strategic decision-making.
With rising healthcare consumerism, increasing collaborations between pharma and tech companies, and expanding evidence of clinical efficacy, the digital therapeutics market is poised to remain on a strong growth path through 2032.
Explore the latest trends and growth drivers in the Digital Therapeutics market-download your sample report now https://www.delveinsight.com/report-store/digital-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Digital Therapeutics Market Report
• The digital therapeutics market is projected to grow at a CAGR of 27.73% from 2025 to 2032.
• As per DelveInsight estimates, North America is anticipated to dominate the global digital therapeutics market during the forecast period.
• Notable Digital Therapeutics companies such as Limbix Health, Inc, GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc, CANARY HEALTH, Noom, Inc, Omada Health Inc, Welldoc, Inc, 2Morrow, Inc, ResMed, Teladoc Health, Inc, Fitbit Health Solutions, Huma, and several others are currently operating in the Digital Therapeutics market.
• In April 2025, Click Therapeutics received FDA marketing authorization for CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in patients aged 18 and older. The therapy is intended for adjunctive use with acute and other preventive treatments for migraine.
• In February 2025, Swing Therapeutics announced that Stanza, its digital therapeutic for treating fibromyalgia symptoms, received a positive coverage decision from Highmark Health. Highmark's commercial members in Pennsylvania, West Virginia, Delaware, and New York now have access to the treatment by prescription, with insurance reimbursement.
To read more about the latest highlights related to the digital therapeutics market, get a snapshot of the key highlights entailed in the global digital therapeutics market report here https://www.delveinsight.com/report-store/digital-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Digital Therapeutics Overview
The digital therapeutics (DTx) market represents a rapidly emerging segment within healthcare, delivering evidence-based therapeutic interventions through software to prevent, manage, or treat medical conditions. Unlike general wellness apps, digital therapeutics undergo rigorous clinical validation and regulatory scrutiny to ensure safety and efficacy, and many are prescribed alongside or in place of traditional treatments.
DTx solutions are transforming care for a wide range of chronic and behavioral conditions, including diabetes, obesity, cardiovascular diseases, mental health disorders, insomnia, respiratory conditions, and migraine, among others. These therapies leverage mobile apps, wearable sensors, AI, and cloud-based platforms to drive behavior change, improve patient adherence, and personalize care.
Digital Therapeutics Market Insights
North America is expected to dominate the digital therapeutics market in 2023, driven by increasing demand from both physicians and patients, a rising chronic disease burden, growing adoption of remote patient monitoring and telemedicine, and the strong presence of key market players.
According to the Administration for Community Living (2024), individuals aged 65 and older represented 17.3% of the U.S. population in 2022, a figure projected to rise to 22% by 2040. The growing geriatric population-more vulnerable to chronic diseases such as major depressive disorder (MDD)-is expected to fuel demand for digital therapeutics, which offer accessible, scalable, and cost-effective tools to complement traditional care.
Favorable regulatory approvals are further accelerating growth in the digital therapeutics market. For example, in April 2024, the U.S. FDA granted marketing clearance to Otsuka America Pharmaceutical, Inc. for Rejoyn, a prescription digital therapeutic app designed to treat MDD in adults currently receiving antidepressant therapy.
Additionally, rising healthcare IT investments, improved digital infrastructure, strong government support, the emergence of innovative startups, growing smartphone penetration, and advancements in internet connectivity are creating a highly favorable environment for the digital therapeutics market in North America.
Major players contributing to the region's market landscape include Proteus Digital Health, Inc., Omada Health, Inc., WellDoc, Inc., and Livongo Health, Inc., among others.
Overall, these combined factors are expected to drive sustained growth in the digital therapeutics market across North America during the forecast period from 2025 to 2032.
To know more about why North America is leading the market growth in the digital therapeutics market, get a snapshot of the Digital Therapeutics market outlook here https://www.delveinsight.com/report-store/digital-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Digital Therapeutics Market Dynamics
As per the International Diabetes Federation (2022), around 537 million people were living with diabetes globally in 2021. This number is projected to rise to approximately 643 million by 2032 and 783 million by 2045.
Digital therapeutic (DTx) applications such as Blue Star, Diabeo System, Livongo Diabetes Program, and Tidepool leverage web-based platforms and cloud technologies to deliver personalized, evidence-based management of chronic, behavior-driven conditions like diabetes. These solutions enhance patient engagement, promote lifestyle modification, and enable continuous glycemic monitoring, thereby improving therapeutic outcomes. The increasing diabetes prevalence is expected to fuel demand for digital therapeutics, propelling the overall digital therapeutics market.
Market growth is further supported by the rising adoption of smartphones in both developed and developing regions, the affordability of digital health tools, and growing demand for patient-centric and integrated healthcare. According to Kepios, 4.27 billion people globally were internet users as of April 2021-over 60% of the population-a figure expected to increase and drive greater awareness and adoption of smart health technologies.
Additionally, the growing focus of key industry players on developing advanced, accessible digital solutions is expected to accelerate market expansion. For example, in July 2022, AmerisourceBergen Corporation launched DTx Connect, an integrated platform that streamlines access to physician-ordered digital therapeutics and diagnostics by connecting directly with electronic medical records (EMR).
Overall, these factors are driving the growth of the digital therapeutics market through the forecast period (2025-2032). However, challenges such as cybersecurity and privacy concerns, along with evolving payment models, could pose hurdles to wider adoption.
Get a sneak peek at the digital therapeutics market dynamics @ https://www.delveinsight.com/report-store/digital-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Coverage: Global
Study Period: 2022 to 2032
Digital Therapeutics Market CAGR: ~27.73%
Key Digital Therapeutics Companies: Limbix Health, Inc, GAIA AG, BigHealth, DarioHealth Corp, HYGIEIA, Akili, Inc, Pear Therapeutics (US), Inc, CANARY HEALTH, Noom, Inc, Omada Health Inc, Welldoc, Inc, 2Morrow, Inc, ResMed, Teladoc Health, Inc, Fitbit Health Solutions, Huma, and others.
Digital Therapeutics Market Segmentation
Market Segmentation By Application: Prevention, Management, and Treatment.
Market Segmentation By Indication: Diabetes, Obesity, Cardiovascular Diseases, Respiratory Diseases, and others.
Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.
Which MedTech key players in the digital therapeutics market are set to emerge as the trendsetter, explore @ https://www.delveinsight.com/report-store/digital-therapeutics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Digital Therapeutics Market Report Introduction
2. Digital Therapeutics Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Digital Therapeutics Market Key Factors Analysis
6. Digital Therapeutics Market Porter's Five Forces Analysis
7. Digital Therapeutics Market Layout
8. Digital Therapeutics Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Digital Therapeutics Market to Witness Transformative Growth Through 2032 - Market Insights, Competitive Landscape, and Forecast | DelveInsight here
News-ID: 4057966 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Therapeutics
Adrenomyeloneuropathy Market: Epidemiology, Therapies, Companies, DelveInsight | …
Adrenomyeloneuropathy emerging therapies are expected to boost the Adrenomyeloneuropathy Market in the upcoming years.
DelveInsight has launched a new report on "Adrenomyeloneuropathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Adrenomyeloneuropathy, historical and forecasted epidemiology as well as the Adrenomyeloneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover about the Adrenomyeloneuropathy market report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the…
Pompe Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Genzyme …
Pompe Disease emerging therapies, such as MYOZYME (alglucosidase alfa), LUMIZYME, AAV2/8-LSPhGAA, Avalglucosidase alfa, and others, are expected to boost the Pompe Disease Market in the upcoming years.
DelveInsight has launched a new report on "Pompe Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Pompe Disease, historical and forecasted epidemiology as well as the Pompe Disease market trends in the United States, EU5 (Germany, Spain,…
Dark Genome Therapeutics Market Deep Research Report with Forecast to 2032 | myN …
The qualitative latest Research report (2025-2032) on the Dark Genome Therapeutics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/133611
Focused on growth…
Hodgkin's lymphoma Therapeutics Market Size Report 2032 | Affimed Therapeutics, …
DelveInsight's "Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Hodgkin's Lymphoma, historical and forecasted epidemiology as well as the Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United kingdom and Japan.
Discover Key Insights into the Hodgkin's lymphoma Market with DelveInsight's In-Depth Report @ Hodgkin's lymphoma Market Size- https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Hodgkin's…
CRISPR Therapies Pipeline 2024 | Intellia Therapeutics, CRISPR therapeutics, Rep …
DelveInsight's, "CRISPR Therapies Pipeline Insight 2024" report provides comprehensive insights about 25+ CRISPR Therapies Companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR Therapies therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive CRISPR Therapies pipeline products in this space.
Key Takeaways from…
Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant…
